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Abstract
Little is known about whether clones of ectopic, non-muscle stem cells contribute to muscle regeneration. Stem/progenitor
cells that are isolated for experimental research or therapeutics are typically heterogeneous. Non-myogenic lineages in a
heterogeneous population conceptually may compromise tissue repair. In this study, we discovered that clones of
mononucleated stem cells of human tooth pulp fused into multinucleated myotubes that robustly expressed myosin heavy
chain in vitro with or without co-culture with mouse skeletal myoblasts (C2C12 cells). Cloned cells were sustainably Oct4+,
Nanog+ and Stro1+. The fusion indices of myogenic clones were approximately 16–17 folds greater than their parent,
heterogeneous stem cells. Upon infusion into cardio-toxin induced tibialis anterior muscle defects, undifferentiated clonal
progenies not only engrafted and colonized host muscle, but also expressed human dystrophin and myosin heavy chain
more efficaciously than their parent heterogeneous stem cell populations. Strikingly, clonal progenies yielded ,9 times
more human myosin heavy chain mRNA in regenerating muscles than those infused with their parent, heterogeneous stem
cells. The number of human dystrophin positive cells in regenerating muscles infused with clonal progenies was more than
,3 times greater than muscles infused with heterogeneous stem cells from which clonal progenies were derived. These
findings suggest the therapeutic potential of ectopic myogenic clones in muscle regeneration.
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Introduction
Much knowledge has been gained on the capacity of muscle
derived stem/progenitor cells in muscle repair [1–3]. However,
autologous muscle-derived cells in muscular dystrophy patients can
be scarce as a therapeutic cell source. Ectopic, non-muscle derived
stem/progenitor cells may act as adjunctive or alternative cell
sources for muscle regeneration. Bone marrow-derived stem/
progenitor cells fuse with degenerated muscle fibers in mdx mice,
and participate in muscle regeneration [4]. MyoD positive, adipose-
derived stem cells merge with native myoblasts in mdx mice in vitro,
andrestoredystrophin expressioninvivo[5].Humanfetalbloodcells
differentiate into myogenic cells, and upon continuous exposure to
galectin-1, engraft into toxin-induced or mdx muscles [6]. Pericytes
isolated from blood vessels of human skeletal muscle engraft in mdx
mice and express human dystrophin [7]. Intramuscular or intra-
arterial injections of dental pulp cells into muscular dystrophy dogs
lead to sparse engraftment and faint dystrophin expression, despite
the infusion of a large number of cells (6610
7/mL) [8]. However,
mostectopicstem cellspreviously used for muscle healing have been
heterogeneous. Non-myogenic cells of the heterogeneous popula-
tion conceptually may compromise the efficacy of muscle repair.
The suboptimal efficacy of heterogeneous stem cells in muscle
regeneration has prompted recent interest in exploring single cell
clones. A single muscle stem cell depleted of endogenous satellite
cells infused into the tibialis anterior muscles of mice is capable of
substantial self-renewal and differentiation in vivo [9]. Single cell
clones isolated from mdx mice express several characteristic
markers and show multipotency, and engraft with host muscle
upon in vivo transplantation [10]. However, a direct comparison of
the efficacy of heterogeneous stem cells and their clonal progenies
has yet to be made. Here, we discovered that several clones of
ectopic, heterogeneous stem/progenitor cell populations isolated
from human tooth pulp were particularly prone to myogenic
differentiation. These clones fused into multinucleated cells ex vivo
and robustly expressed myosin heavy chain (MHC) in either
chemically defined medium or upon co-culture with mouse skeletal
myoblasts (C2C12 cells). We then infused a Nanog+, Oct4+,
Stro1+, but CD133- and CD146- clone into cardiotoxin-injured
tibialis anterior (TA) muscles in NOD/SCID mice. This ectopic,
undifferentiated clone not only engrafted, but also expressed
human-specific dystrophin and MHC, more efficaciously than their
parent heterogeneous cells. Together, myogenic clones of hetero-
geneous stem cells may have value in muscle regeneration.
Materials and Methods
Ethics Statement
All research involving human participants was approved by
Columbia University Medical Center Institutional Review Board
(IRB). Dental stem/progenitor cells (DSCs) were isolated from
infection-free deciduous teeth of 6 donors (5–9 yrs old) following
IRB approval and informed parent consent. Consent statement was
verbal because the study materials were regarded as medical waste.
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Tooth pulp was minced and digested with collagenase (3 mg/
mL) and dispase (4 mg/mL) for 1 h at 37uC. Mononucleated and
adherent cells were isolated by single cell suspension and passage
of the cells through a 70-mm strainer (BD, Franklin Lakes, NJ).
The isolated cells were cultured in Dulbecco’s Modified Eagle
Medium: Nutrient Mixture F-12 (DMEM/F12, 1:1, Invitrogen,
Carlsbad, CA) supplemented with 10% Fetal bovine serum (FBS,
Atlanta Biological, Lawrenceville, GA) and 1% Antibiotic-
Antimycotic (Atlanta Biologicals) at 37uC and 5% CO2 with
medium change twice a week. The growing culture was
maintained for 2 wks, and then washed twice in PBS, dissociated
in 0.25% Trypsin-EDTA (Mediatech, Manassas, VA).
Cloning
A total of 42 clones were established by limiting dilution from
heterogeneous DSCs. Passage 0 heterogeneous cells were seeded in
96-well platesata concentrationof3cells/mLwith 200 mLmedium
per well. After 24 hrs, each of the wells with only one cell was
selected for clonal expansion at 37uC and 5% CO2. After 3–4 wks,
single-cell derived clones were treated with 0.25% trypsin-EDTA
and seeded into 24-well plates for further expansion. Clonal
progeny was transferred to 6-well plates upon ,80% confluence,
and at 37uC and 5% CO2 with medium change twice a week.
Clonalprogeny was passaged for the tested ,20 doublings.Passage-
5 clonal progeny cells were used for in vivo cell delivery.
Self renewal and myogenic differentiation
Heterogeneous cells and clonal progenies were separately plated
at a density of 5610
3 cells per cm
2, and passaged. At each
passaging, cell numbers were counted using a haemocytometer.
The doubling time was calculated as the number of divisions=log2
(number of cells at subculture/number of cell seeded) [11]. At
passage 2, 5, and 17 for heterogeneous DSCs and P5 and P9 for
clonal progenies, CD34, CD44, CD105, CD133, CD146, stro1,
Oct4 and Nanog were assayed by immunefluorescent antibodies
and cell counting in at least 10 representative fields. At least 600
cells were counted per cell surface or nuclear marker in triplicates
(Table 1). Subpopulations of heterogeneous cells and clonal
progenies were plated at a density of 3,000 cells/cm
2 in 24 well
plates and exposed to myogenic differentiation medium, consisting
of 97% DMEM, 2% horse serum and 1% Antibiotic-Antimycotic.
Myogenic clones were confirmed by immunocytochemistry and
real-time PCR for the expression of myosin heavy chain (MHC),
and the formation of multi-nucleated myotube-like structures.
Myogenic clones were distinguished from other clones of the same
ectopic stem/progenitor cell population: myogenic clones readily
transformed into MHC-positive myotube-like structures, whereas
non-myogenic clones failed to express MHC or form myotube-like
structures. In parallel with myogenic differentiation in chemically
defined medium, we also attempted to induce myogenic
differentiation by co-culture of heterogeneous cells and clones
(2500/cm
2) separately with mouse skeletal myoblasts (C2C12 cells)
(2500/cm
2) for 3 days in DMEM (high glucose) supplemented
with 10% FBS and 1% Antibiotic-Antimycotic. Then, the co-
cultured cells were treated with myogenic differentiation medium
consisting of 97% DMEM (high glucose) supplemented with 2%
horse serum and 1% Antibiotic-Antimycotic for 5 additional days.
The cells were then fixed in 10% formalin and stained with anti-
human nuclei and anti-MHC antibodies.
In vivo cell engraftment
Ethics Statement. All animal work was approved by the
IACUC and conducted according to relevant national and
international guidelines. The work further adhered to NIH
Animal Research guidelines. Following IACUC approval, NOD/
SCID mice (8–10-wk-old) were anesthetized with 1–3% Isoflurane,
followed by multi-point injection of Cardiotoxin I from Naja naja
atra(Sigma,C3987,0.5 mgi n3 0ml PBSper muscle) intheright TA
muscle (N=10). The left TA muscle was injected with PBS (same
volume) and served as control. Twenty-four hrs following
cardiotoxin injections, human cells (1610
6) were multi-point
infused into the injured TA muscles. Mice were sacrificed 4 wks
later, followed by careful dissection of the TA muscles and
embedding using OCT mounting matrix. The blocks were
sectioned at 7-mm thickness using a cryostat. Human cell
incorporation was assessed as the number of human dystrophin-
positive myofibers divided by total myofibers per section using serial
sections at 100-mm intervals along the entire muscle length. Human
myosin heavy chain expression was further confirmed by Taqman
real-time PCR using human specific primers (details below).
Immunocytochemistry and immunohistochemistry
Heterogeneous cells and clonal progenies were incubated with
the following primary antibodies for immunofluorescence: mouse
monoclonal anti-CD-34 (sc-65261; Santa Cruz Biotechnology),
CD105 (ab11414; Abcam), anti-CD146 (ab11372; Abcam), anti-
flk1 (sc-57135; Santa Cruz Biotechnology), anti-Stro1 (MAB4315;
Millipore), anti-human nuclei (HuNu, MAB1281; Millipore), anti-
human dystrophin (dys, MAB1690, Millipore); rabbit polyclonal
anti-CD44 (ab-51037; Abcam), anti-CD117 (ab16832; Abcam),
anti-Oct4 (ab19857; Abcam), anti-Nanog (ab21603; Abcam), anti-
MHC (MHC, sc-20641; Santa Cruz Biotechnology). Cells were
washed in PBS, fixed with 10% formalin and permeabilized with
0.1% Triton X-100, and then blocked with buffer (LI-COR
Biosciences). After incubation with primary antibodies, cells were
washed and incubated with Alexa FluorH 546 secondary
antibodies (1:200, Invitrogen) for CD117, Oct4, Nanog and
MHC; Alexa FluorH 488 nm and 594 nm secondary antibodies
(1:200, Invitrogen) for CD106, CD146, flk1, human nuclei and
human dystrophin staining. Stro1 was detected by goat anti-mouse
IgM-FITC (1:200, sc-2859; Santa Cruz Biotechnology). Nuclei
were visualized by DAPI staining. Muscle sections were air-dried
and immunostained against human dystrophin, human nuclei and
human PECAM [12].
Real-Time RT-PCR Analysis
Real-Time RT-PCR was performed by extracting RNA from
culture cells and muscle tissue. Total RNA was isolated using
Table 1. Molecular markers of the native, heterogeneous
dental stem/progenitor cell population and two myogenic
clones, B6 and C3.
DSCs B6 C3
P2 P5 P17 P5 P9 P5 P9
CD133 39/642 0/623 0/904 0/813 0/672 0/627 0/627
CD146 229/606 114/702 0/782 0/813 0/672 0/627 0/627
Stro1 67/689 27/629 1/832 620/684 639/703 683/714 586/637
Oct4 572/603 590/630 - 692/710 520/622 642/724 411/710
Nanog 580/624 623/671 - 518/629 592/632 556/659 361/673
Frequency of positive marker expression expressed as the number of positive
cells among total counted cells. P: cell passage. ‘‘-’’: absent expression.
doi:10.1371/journal.pone.0013547.t001
Myogenic Stem Cell Clones
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tion was measured using UV spectrometer. A total of 1-mg RNA
was used to synthesize cDNA (iScript
TMcDNA Synthesis Kit,
BIO-RAD, Hercules, CA). The primer sets for real-time PCR
assays were pre-designed TaqManH human myosin heavy chain
and human PECAM primers labeled with Fam (Applied
Biosystems, Foster City, CA). GAPDH was used as housekeeping
gene. The expression of candidate genes was determined with
TaqManH probe-based Universal PCR Master Mix (Applied
Biosystems) using 7300 Real-Time PCR System (Applied
Biosystems). The conditions for real-time PCR were as follows:
50uC, 2 min; 95uC,10 min; followed by 40 amplification cycles
(95uC,15 s; 60uC, 60 s). Specific gene expression in each sample
was calculated as DDCt value.
Statistical analysis
Power analysis was used to calculate sample sizes for in vivo
experiments. For normal distribution, quantitative data of control
and treated groups were subjected to One-way ANOVA and post-
hoc Bonferroni tests. For skewed data, non-parametric Kruskal-
Wallis tests were used.
Results
Stemness markers and population doubling
Passage 2 (P2), heterogeneous DSCs expressed Stro1, CD146
and CD133 (Fig. 1A–C), but did not express CD34, CD44,
CD105 or flk1 (data not shown). However, the number of Stro1,
CD146 and CD133 positive cells decreased with passaging. At P5,
few CD133+ cells remained, whereas Stro1+ and CD146+ cells
decreased substantially (Fig. 1D). By P17, Stro1, CD133 and
CD146 were virtually absent in heterogeneous cells (Fig. 1D).
Heterogeneous DSCs continued to undergo population doubling
(PD) during the tested 10 passages (Fig. 2A). The two isolated
myogenic clones, B6 and C3, showed similar morphology and PD
kinetics to their parent cell population (Fig. 2A) (without
statistically significant differences in PD), indicating that the
isolated clones by limiting dilution from heterogeneous cell
populations were as capable of self renewal as their parent
mononucleated and adherent cell populations.
Out of the established 42 clones, cells from a total of 3 clonal
progenies fused into multi-nucleated, MHC+ myotubes, including
B6 and C3 (see below). The B6 and C3 clones were continuously
passaged every 3–4 days over the tested 10 passages without
apparent compromise in their doubling rate (Fig. 2A). Quanti-
tatively, the percentage of heterogeneous cells that expressed
CD146, Stro1 and CD133 were 37.7%, 9.7% and 6.0% at P2,
but decreased to 16.3%, 4.3% and 0% by P5 (Fig. 2B).
Strikingly, B6 and C3 clones were overwhelmingly Oct4+,
Nanog+ and Stro1+, and sustained the expression of these
markers up to the tested 5 passages (Fig. 2B; Fig. 2C–E for B6;
Fig. 2F–H for C3). Contrastingly, B6 and C3 failed to express
CD133 and CD146 (Fig. 2B). There were minimal differences
between B6 and C3 clones in their morphology, population
doubling rates, molecular marker expression or differentiation
potential.
Clonal progeny differentiated into myotube-like
structures
In contrast to their typical spindle shape (Fig. 3A), mononu-
cleated and adherent cells of the tooth pulp upon 4-wk exposure to
chemically defined myogenic differentiation medium assumed a
somewhat rounded morphology (Fig. 3B). However, these
heterogeneous stem/progenitor cells failed to fuse into multinu-
cleated cells or express MHC (Fig. 3C). Strikingly, B6 and C3
exposed for 4 wks in the same chemically defined medium readily
fused into multi-nucleated myotube-like structures (Fig. 3D,E)
and robustly expressed MHC (Fig. 3F,G). Remarkably, fusion
Figure 1. Characterization of heterogeneous stem/progenitor cells of the dental pulp. Immunostaining at passage 2 for Stro1(green) (A),
CD146 (green) (B) and CD133 (red) (C) over DAPI-stained nuclei. Scale bars: 100 mm. D: Quantitative expression of CD146, Stro1 and CD133 at
passages 2, 5 and 17 (N=3).
doi:10.1371/journal.pone.0013547.g001
Myogenic Stem Cell Clones
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culture with mouse skeletal myoblasts (C2C12). Overall, ,27% of
B6 and ,30% of C3 cells fused into multi-nucleated, MHC+
myotube-like structures that were quantified from multiple plates.
Quantitative real-time PCR analysis revealed significantly greater
MHC expression by B6 and C3 cells heterogeneous DSCs, from
which B6 and C3 were cloned (Fig. 3H).
Upon co-culture with C2C12 cells, B6 and C3 also fused into
multinucleated cells that expressed MHC within 1 wk (Fig. 4A,B).
Human nuclear staining confirmed that multi-nucleated myotube
structures contained both human and mouse nuclei (Fig. 4A,B).
Upon co-culture of heterogeneous DSCs, 3 human cells (with
positive human nuclear staining, HuNu) were identified among
1,475 cells, yielding a fusion index of 0.2% (Fig. 4C). In
comparison, 52 human cells (with positive human nuclear staining,
HuNu) were identified out of 1,551 cells when B6 clones were co-
cultured with C2C12 cells, yielding a fusion index of 3.35% (Fig.
4C). Thus, the fusion index of myogenic clones was approximately
16–17 folds greater than their parent, heterogeneous stem cells.
Furthermore, 51 human cells (with positive human nuclear
staining, HuNu) were identified out of 1,482 cells when C3 clones
were co-cultured with C2C12 cells, yielding a fusion index of
3.44% (Fig. 4C). Quantitative PCR revealed that co-culture of
either B6 or C3 with C2C12 yielded significantly more human
myosin heavy chain (MHC) mRNA than co-culture of heteroge-
neous DSCs with C2C12 (Fig. 4D).
Myogenic clones engrafted into cardiotoxin paralyzed
muscles in vivo
The tibialis anterior (TA) muscles of NOD/SCID mice (N=10)
were injured by cardiotoxin (CTX) injection. Twenty-four hrs
following CTX injection, B6 cells (at P5) and their parent,
heterogeneous cells (both at 16106 cells/mL) were infused
separately into the injured TA muscles (N=4 for B6; N=6 for
heterogeneous cells). CTX injured, PBS-injected and uninjured
TA muscles without cell infusion served as controls. In comparison
to peripherally located nuclei in the representative normal TA
muscle specimen (Fig. 5C), abundant centralized nuclei were
present upon infusion with heterogeneous cells or B6 clones (Fig.
5A and 5B), suggesting neomyofiber formation and muscle
regeneration. Human nuclear staining confirmed the presence of
engrafted (human) B6 cells (arrows in Fig. 5D,F). B6 infused cells
showed substantial human dystrophin expression (Fig. 5E,F).
Strikingly, B6-infused TA muscles expressed ,9 times more
human myosin heavy chain mRNA than TA muscles infused with
their parent, heterogeneous DSCs (Fig. 5G) (p=0.002). Addi-
tionally, the number of human dystrophin positive cells per section
of B6-infused TA muscles was more than 3 times greater than that
Figure 2. Myogenic clones in comparison with their parent stem/progenitor cells. A: Cumulative population doubling (PD) of two
myogenic clones and their parent stem/progenitor cells showing a lack of statistically significant differences in PD kinetics. B: Expression of CD146,
Stro1, CD133, Oct4 and Nanog by the two tested myogenic clones, B6 and C3, as well as their parent stem/progenitor cells. P: cell passage. Strikingly,
B6 and C3 were overwhelmingly Oct4+, Nanog+ and Stro1+, and sustained the expression of these markers up to the tested 5 passages. C–H:
Representative immunofluorescence of Stro1, Oct4 and Nanog by the two identified myogenic clones (passage 5) merged with DAPI-stain nuclei.
Scale bar: 100 mm.
doi:10.1371/journal.pone.0013547.g002
Myogenic Stem Cell Clones
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13547Figure 3. Myogenic potential of clonal progeny of ectopic dental stem cells in chemically defined medium. A: Phase contrast image of a
representative heterogeneous dental stem cell (DSC) population showing typical spindle-shaped cells. Upon exposure to chemically defined medium,
DSCs assumed spherical shape but failed to fuse into multinucleated cells (B) or express myosin heavy chain (C). Strikingly, two representative clones
(B6 and C3) in chemically defined medium for 4 wks readily fused into tubular structures (D,E) that are positive for myosin heavy chain (MHC)
immunoblotting (F,G). Quantitatively, MHC mRNA expression is significantly greater by B6 and C3 cells than their heterogeneous parent cells (DSC)
(H). The y axis represents fold change related to heterogeneous DSC. Scale bar: 100 mm.
doi:10.1371/journal.pone.0013547.g003
Figure 4. Myogenic potential of clonal progeny of ectopic dental stem cells upon co-culture with mouse skeletal myoblasts. Upon
co-culture with mouse myoblast cell line (C2C12 cells) for 1 wk, some of the B6 and C3 cells again fused into multinucleated cells (A,B). Human
nuclear staining indicates that the presence of human nuclei in some of the fused myotube like, MHC positive structures (A,B). Quantitatively, human
nuclear fusion index (C) and human MHC mRNA expression of B6 and C3 (D) are significantly greater than DSC+C2C12 group. In (D), y axis represents
fold change related to DSC+C2C12 group. Scale bar, 50 mm.
doi:10.1371/journal.pone.0013547.g004
Myogenic Stem Cell Clones
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5H) (p=0.008).
Infused B6 and DSCs also formed chimeric blood vessels
together with host endothelial cells. Some of the host blood vessel
structures among muscle fibers showed positive human cell
immunostaining with human-specific PECAM (Fig. 6A,B).
However, human PECAM expression upon B6 infusion failed to
show statistical advantage over human PECAM expression upon
the heterogeneous DSCs infusion (Fig. 6C) upon quantitative
real-time PCR analysis.
Discussion
We discovered that clonal progenies of ectopic stem cells with
robust in vitro myogenic capacity not only engraft in injured
muscle, but also yield dystrophin and myosin heavy chain.
Myogenic clones from ectopic stem cells, in this case dental stem
cells, that natively do not differentiate into skeletal muscle, are
more efficacious towards myogenic differentiation in vivo than their
heterogeneous parent stem/progenitor cell populations. In
comparison with the majority of previous approaches of muscle
regeneration with heterogeneous stem/progenitor cells, the
present findings demonstrate the potential value of myogenic
clones out of ectopic heterogeneous cells for muscle repair. Some
of the previous approaches for muscle repair have relied primarily
on heterogeneous stem/progenitor cell populations including
either muscle-derived or non-muscle stem cells [13–16]. Myogenic
clones that are infused in muscle defects appear to generate high
yield muscle cells in vivo, as shown by self-renewal and
differentiation by a single muscle stem cell [9] and the expression
of human dystrophin and MHC in the present work. Given the
apparent biological advantage of myogenic clones, what are the
issues for their potential application as a therapeutic cell source?
The current view is that myogenic clones are scarce among ectopic
stem cell populations. However, recent demonstration of robust
self-renewal and differentiation capacity of a single muscle stem
cell [9] provides grounds for exploring whether myogenic clones
are capable of muscle healing. It is also possible, and yet untested,
that muscle-derived stem cells or satellite cells yield more
numerous myogenic clones than ectopic stem cells. Thus, cell
therapies for muscle repair are likely effective by taking advantage
of myogenic clones of both muscle-derived and ectopic stem cells.
Dental stem cells were used as a model for ectopic stem cells in the
present work because 1) DSCs can be readily isolated from
Figure 5. Engraftment of undifferentiated ectopic stem cell clone in damaged muscle. The tibialis anterior (TA) muscles in NOD/SCID mice
were injured by multi-point cardiotoxin (CTX) injection. 24 hrs following CTX injections, dental stem cells (DSC) and a tested clone (B6) were
separately infused in CTX-injured TA muscles with contralateral TA muscles as controls. A: H&E staining shows the presence of centralized nuclei in
the representative DSC infused sample. B: The representative B6 infused sample showed abundant centralized nuclei. In contrast, the representative
normal TA muscle has peripheral nuclei (C). Immunohistochemistry staining (brown) of human specific nuclei (D) and immunefluorescent staining of
human specific dystrophin (green) and human nuclei (red) (E,F) indicates the presence of transplanted human cells in host TA muscle in the
representative B6 infused group. We then harvested in vivo muscle samples, isolated RNA for real-time PCR analysis of myogenic differentiation in
vivo. Quantitative RT-PCR assay revealed that human MHC gene expression in B6 infusion group after 4 wk injection is ,8 times greater than DSC
infusion group (N=3, **p,0.01) (G). Quantification of human dystrophin positive cells present in the tibialis anterior (TA) muscle shows that the
expression of human dystrophin mRNA was ,3 times greater following B6 infusion than DSC infusion (N=3, **p,0.01) (H). In (D) and (F), the arrows
indicate the human nuclei. In G, y axis represents fold change relative to heterogeneous DSC. Scale bars: A–C, E, F: 50 mm; D: 20 mm.
doi:10.1371/journal.pone.0013547.g005
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thus have great potential for cell therapies, and 2) DSCs natively
do not differentiate into muscle cells and therefore qualify as
ectopic stem cells for myogenic differentiation.
One of the striking findings in the present study is that ectopic
stem cells isolated from dental pulp fail to fuse into multinucleated
myofiber-like structures despite exposure to chemically defined
medium that is known to induce myogenic fusion of several other
postnatal stem cell populations such as bone marrow or adipose
[4,17]. The mechanisms of cell fusion are not well understood,
although several cellular.
machineries including cell membrane proteins and associated
signaling appear to be highly conserved for cell fusion and
differentiation into myocytes [18–19]. Few myogenic stem/
progenitor cells are present among heterogeneous stem cells of
dental pulp in the present study: only 3 out of 42 clones showing
myogenic potential. It is conceivable that the scarce myogenic cells
fail to fuse with adjacent cells most of which are not myogenic and
do not express the same cell surface proteins that are putatively
important for cell fusion. Conversely, myogenic clones in the
present study, B6 and C3, readily fuse even without co-culture
with mouse myoblast cell line, C2C12 cells which are known to
fuse with other myocyte-like cells.
We found a lack of statistically significant differences in mRNA
expression of human PECAM by the transplanted heterogeneous
DSCs and their clonal progeny cells. This appears to suggest that
while myogenic clones of ectopic stem cells show advantage in
myogenic capacity, they may not necessarily elaborate more
vasculature. Previous work has shown that transplanted stem/
progenitor cells are capable of co-endothlializing blood vessels with
host cells [20–21,12,22]. Whereas the isolated myogenic clones are
capable of engrafting with host muscle fibers and yield myosin heavy
chain without necessarily relying on enhanced angiogenesis. Coupled
with the paucity or decreases in the expression of CD146, an
endothelial progenitor marker by either heterogeneous DSCs or their
myogenic clones, it is somewhat surprising that the derived myogenic
clones appear to be capable of muscle repair without necessarily an
accompanied enhancement in angiogenesis. However, much addi-
tional work is warranted to ascertain the roles of angiogenesis in
muscle regeneration by clones of ectopic stem/progenitor cells. The
myogenic clones in the present work are sustainably Oct4+,N a n o g +
and Stro1+, but CD133- and CD146-. As parent heterogeneous cells
deplete their expression of Stro1, CD133 and CD146, the myogenic
clonal progenies maintained robust expression of Stro1, Oct4 and
Nanog. This appears to be consistent with weak CD133 and CD146
expression by human pericytes in muscle regeneration [7]. Much
meritorious effort has been directed towards transcriptional control of
myogenic differentiation from stem/progenitor cells. The present
data represent a rare glimpse of in vivo muscle repair by clonal
progenies of heterogeneous stem/progenitor cells with robust
capacity for myogenic differentiation in vitro.
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